The objective of the trial is to investigate the efficacy and safety of nerandomilast in patients with SSc at an oral dose of 18 mg bid compared to placebo on top of standard of care.

We are requesting a reliance agreement with Advarra for a randomized control trial using the ATTN201 device for the treatment of OCD. The ATTN201 device will provide low-intensity focused ultrasound to the subthalamic nucleus (STN). The device is a safe, easy-to-use, helmet-like device meant to be used in-clinic or at home. The treatment will consist of 8 ultrasound sessions over the course of 4 weeks.

This is a multi-site, interventional trial which evaluates the efficacy of delgocitinib cream for treating mild to severe lichen sclerosus (LS) in adults. The trial is conducted in 2 parts. Part 1 of the trial enrolls female participants with LS and results in the selection of the optimal dose for Part 2. The selected dose will then be evaluated in Part 2, which will enroll both female and male participants. Assessment of efficacy and safety of delgocitinib cream in male participants with LS will be evaluated in a substudy. The trial primarily focuses on female subjects, because LS is more likely to affect females than males. For each participant, the trial will last at least 55 weeks and up to 60 weeks.